Visualizing the Interactions Between a Potential Drug and Its Proposed Target LigandScout, released this month by Inte:Ligand (www.inteligand. com), features a 3-D pharmacophore modeling approach that ...
A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.
Antibodies, as powerful therapeutic agents, have demonstrated immense potential in treating a range of diseases, from cancer to infectious diseases. Recent advances in artificial intelligence (AI) and ...
New AI Models-as-a-Service offering to integrate in-silico design with experimental data to continuously improve predictive power and accelerate scientific innovation Across life sciences and ...
Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual goal of in silico drug design. While Absci's stock has benefitted from AI hype in ...
CAMBRIDGE, Mass. and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of ...
Wahbi El-Bouri receives funding from The Royal Society and EPSRC. He is affiliated with the Avicenna Alliance and InSilico UK communities that seek to drive adoption of in silico clinical trials for ...
New AI Models-as-a-Service offering to integrate in-silico design with experimental data to continuously improve predictive power and accelerate scientific innovation WALTHAM, Mass.--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback